Literature DB >> 10563309

Glucosylceramide synthase: assay and properties.

J A Shayman1, A Abe.   

Abstract

Glucosylceramide synthesis is a key step in the formation of most mammalian glycosphingolipids. The expanding number of cellular functions that may be glycosphinolipid dependent and the identification of this glucosylceramide synthase as a potential therapeutic target for several sphingolipid storage disorders necessitate the availability of a reliable assay for glucosylceramide synthase. Coupled with the recent sequencing of this enzyme, the liposome-based assay utilizing a single extraction step should aid in the understanding of this critical early pathway in glycosphingolipid formation.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10563309     DOI: 10.1016/s0076-6879(00)11065-1

Source DB:  PubMed          Journal:  Methods Enzymol        ISSN: 0076-6879            Impact factor:   1.600


  5 in total

Review 1.  Biosynthesis and immunogenicity of glucosylceramide in Cryptococcus neoformans and other human pathogens.

Authors:  Ryan Rhome; Travis McQuiston; Talar Kechichian; Alicja Bielawska; Mirko Hennig; Monica Drago; Giulia Morace; Chiara Luberto; Maurizio Del Poeta
Journal:  Eukaryot Cell       Date:  2007-08-10

Review 2.  An introduction to plant sphingolipids and a review of recent advances in understanding their metabolism and function.

Authors:  Daniel V Lynch; Teresa M Dunn
Journal:  New Phytol       Date:  2004-01-14       Impact factor: 10.151

3.  Property-based design of a glucosylceramide synthase inhibitor that reduces glucosylceramide in the brain.

Authors:  Scott D Larsen; Michael W Wilson; Akira Abe; Liming Shu; Christopher H George; Paul Kirchhoff; H D Hollis Showalter; Jianming Xiang; Richard F Keep; James A Shayman
Journal:  J Lipid Res       Date:  2011-11-04       Impact factor: 5.922

Review 4.  An introduction to sphingolipid metabolism and analysis by new technologies.

Authors:  Yanfeng Chen; Ying Liu; M Cameron Sullards; Alfred H Merrill
Journal:  Neuromolecular Med       Date:  2010-08-03       Impact factor: 3.843

5.  Optimization of Eliglustat-Based Glucosylceramide Synthase Inhibitors as Substrate Reduction Therapy for Gaucher Disease Type 3.

Authors:  Michael W Wilson; Liming Shu; Vania Hinkovska-Galcheva; Yafei Jin; Walajapet Rajeswaran; Akira Abe; Ting Zhao; Ruijuan Luo; Lu Wang; Bo Wen; Benjamin Liou; Venette Fannin; Duxin Sun; Ying Sun; James A Shayman; Scott D Larsen
Journal:  ACS Chem Neurosci       Date:  2020-10-09       Impact factor: 4.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.